ES2187024T3 - Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona. - Google Patents

Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona.

Info

Publication number
ES2187024T3
ES2187024T3 ES98921701T ES98921701T ES2187024T3 ES 2187024 T3 ES2187024 T3 ES 2187024T3 ES 98921701 T ES98921701 T ES 98921701T ES 98921701 T ES98921701 T ES 98921701T ES 2187024 T3 ES2187024 T3 ES 2187024T3
Authority
ES
Spain
Prior art keywords
testosterone
administration
drug release
release device
precursors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98921701T
Other languages
English (en)
Inventor
Clare Passmore
Claire Gilligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Ireland Ltd
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of ES2187024T3 publication Critical patent/ES2187024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a un dispositivo para la administración intravaginal de medicamentos adecuado para la administración de medicamentos a la mujer o a hembras de animales. El dispositivo comprende testosterona o un precursor de la testosterona en una matriz de polímero, rodeado por una cubierta y que es capaz de liberar la testosterona o el precursor de la testosterona con un patrón de orden básicamente igual a cero sobre una base diaria durante al menos tres semanas. El dispositivo está diseñado para restaurar los niveles de testosterona en circulación hasta una banda fisiológica normal o para inducir niveles de testosterona supraterapéuticos.
ES98921701T 1997-05-07 1998-05-07 Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona. Expired - Lifetime ES2187024T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07

Publications (1)

Publication Number Publication Date
ES2187024T3 true ES2187024T3 (es) 2003-05-16

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98921701T Expired - Lifetime ES2187024T3 (es) 1997-05-07 1998-05-07 Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona.

Country Status (15)

Country Link
US (1) US6416780B1 (es)
EP (1) EP0981327B1 (es)
JP (1) JP2001524124A (es)
CN (1) CN1184957C (es)
AT (1) ATE227120T1 (es)
AU (1) AU741482B2 (es)
CA (1) CA2288046C (es)
DE (1) DE69809222T2 (es)
DK (1) DK0981327T3 (es)
ES (1) ES2187024T3 (es)
IL (1) IL132702A0 (es)
NO (1) NO995419L (es)
NZ (1) NZ501236A (es)
PT (1) PT981327E (es)
WO (1) WO1998050016A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003080018A1 (en) * 2002-03-27 2003-10-02 Galen (Chemicals) Limited Intravaginal matrix drug delivery devices
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
DK1765454T3 (en) 2004-07-02 2016-05-02 Mati Therapeutics Inc Device for submission of treatment medium to eye
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
DK1933810T3 (da) * 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
KR101538748B1 (ko) * 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
EP2359807B1 (en) 2008-02-04 2017-07-26 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
EA201170297A1 (ru) * 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
MX2012004373A (es) 2009-10-14 2012-06-28 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol.
CA2788440A1 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치
CN105377888A (zh) 2013-03-15 2016-03-02 加利福尼亚大学董事会 纤维蛋白溶解的双反应性的有效的Kunitz抑制剂
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
PL2982352T3 (pl) * 2014-06-28 2019-01-31 Laboratorios Andrómaco S.A. Krążek szyjki macicy zawierający progesteron do długotrwałego, przedłużonego i ciągłego uwalniania, stosowany w celu zapobiegania przed przedwczesnym porodem
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
DK3416964T3 (da) 2016-02-19 2021-02-22 Phoenix Molecular Designs 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
PL3458449T3 (pl) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2020023923A1 (en) 2018-07-27 2020-01-30 Xenon Pharmaceuticals Inc. Method for treating epilepsy
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
EP4405344A2 (en) 2021-09-24 2024-07-31 Xenon Pharmaceuticals Inc. Pyridinyl derivatives as sodium channel activators
JP2024534572A (ja) 2021-09-24 2024-09-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ナトリウムチャンネル活性化剤としてのピリジニルアセトアミド誘導体
EP4405347A1 (en) 2021-09-24 2024-07-31 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
GB2079158B (en) * 1980-06-09 1985-01-09 Ahi Operations Ltd Intra-vaginal devices
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) * 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
CA2288046A1 (en) 1998-11-12
DE69809222T2 (de) 2003-08-14
JP2001524124A (ja) 2001-11-27
NO995419D0 (no) 1999-11-05
WO1998050016A3 (en) 1999-02-04
EP0981327B1 (en) 2002-11-06
ATE227120T1 (de) 2002-11-15
EP0981327A2 (en) 2000-03-01
DE69809222D1 (de) 2002-12-12
CN1255056A (zh) 2000-05-31
NO995419L (no) 2000-01-07
DK0981327T3 (da) 2003-03-10
PT981327E (pt) 2003-02-28
US6416780B1 (en) 2002-07-09
IL132702A0 (en) 2001-03-19
WO1998050016A2 (en) 1998-11-12
CN1184957C (zh) 2005-01-19
AU7446998A (en) 1998-11-27
AU741482B2 (en) 2001-11-29
NZ501236A (en) 2002-02-01
CA2288046C (en) 2006-10-03

Similar Documents

Publication Publication Date Title
ES2187024T3 (es) Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona.
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
FI972586A7 (fi) Lääkeainesuspension säädellysti vapauttava antolaite
AU1227899A (en) Osmotic medicament releasing system
CA2298245A1 (en) Matrix controlled release device
BR9812687A (pt) Formulação de comprimido para liberação contìnua para tratar doença de parkinson
AR036972A1 (es) Tableta bioadhesiva de hidratacion progresiva y liberacion sostenida y su uso en la fabricacion de un agente farmaceutico
BR9609663A (pt) Formulações para desprendimento controlado de medicamentos fracamente soluveis
CA2292402A1 (en) Intra-vaginal device for pigs
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
BR9711378A (pt) Forma gal-ncia com libera-Æo prolongada
BR0000358A (pt) Liberação controlada por extrusão de dispersões amorfas sólidas de drogas
EP1499300A4 (en) PHARMACEUTICAL FORMULATIONS WITH IMPROVED BIOAVAILABILITY
ZA200106305B (en) Core tablet for controlled release of gliclazide after oral administration.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
IL113053A0 (en) Targeted release pharmaceutical forms of alfuzosin hydrochloride
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
NZ324674A (en) Rapid release tablet comprising tolfenamic acid, alginic acid and a superdisintegrant
BR0109640A (pt) Forma de droga multiparticulada compreendendo pelo menos duas formas de pélete diferentemente revestidas
Kubek 'Night Mares of the Commonwealth': Royalist Passion and Female Ambition in Aphra Behn's" The Roundheads"
PT8662T (pt) Doseador para distribuir um medicamento inoforo aplicado em especial para tratamento de animais
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
FR2764506B1 (fr) Composition therapeutique ou hygienique a liberation controlee et prolongee de principe(s) actif(s), notamment a usage ophtalmique